Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic agents and products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart TechneLite, a technetium generator for nuclear medicine Xenon-133 to assess pulmonary function Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke Cardiolite, an injectable Tc-99m-labeled imaging agent and RELISTOR for opioid-induced constipation. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients Automated Bone Scan Index that calculates the disease burden of prostate cancer by quantifying the hotspots on bone scans and Cobalt (Co 57), a non-pharmaceutical radiochemical. It provides Thallium-201 to detect cardiovascular disease Gallium-67 to detect various infections and cancerous tumors and Quadramet for severe bone pain associated with osteoblastic metastatic bone lesions. The company also develops PyL for prostate cancer flurpiridaz F 18 to assess blood flow to the heart 1095, a PSMA-targeted iodine-131 labeled small molecule LMI 1195 for neuroendocrine tumors PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic 1404, a Tc-99m labeled small molecule PSMA-AI, an AI-based imaging analysis technology and leronlimab, an investigational humanized monoclonal antibody. It serves radiopharmacies, PET manufacturing facilities, integrated delivery networks, hospitals, clinics, and group practices. The company has strategic partnerships with NanoMab Technology Limited Bausch Health Companies, Inc. GE Healthcare Limited Curium Bayer AG CytoDyn Inc. ROTOP FUJIFILM Toyama Chemical Co. Ltd. Regeneron Pharmaceuticals, Inc. and POINT Biopharma US Inc. The company was founded in 1956 and is headquartered in North Billerica, Massachusetts.